Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
Poor risk patients with mCSPC at study enrollment
De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
You may not be if
Under a randomized-controlled trial with unknown allocation of systemic therapy
Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
Unable to provide written consent by patient and their legal representatives
In the opinion of the treating physician:
conditions which would significantly impair the patient's ability to comply with study procedures and follow up
Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
* another active malignancy
* patient on dialysis
* another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging
Clareo Health | Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
